Rezolute Inc Dossier - Source-backed chat

Rezolute Inc

RZLTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.73

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.07Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $393.7M

Enterprise Value $383.5M

Shares Outstanding 109.8M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rezolute, Inc. is a late-stage clinical biopharmaceutical company focused on developing transformative therapies for orphan endocrine and metabolic diseases. The company's primary value proposition centers on its lead candidate, ersodetug (RZ358), a monoclonal antibody targeting insulin receptor over-activation. While the Phase 3 sunRIZE study in congenital hyperinsulinism (cHI) missed its primary endpoint due to a pronounced study effect, expanded analyses and ongoing FDA discussions provide a potential path forward. Crucially, the pipeline is highly de-risked by positive interim data from the Phase 3 upLIFT study in tumor hyperinsulinism (tHI), where 6 out of 8 participants achieved significant reductions in IV glucose infusion requirements. With a strong cash position and upcoming registrational readouts in H2 2026, Rezolute presents an attractive risk-reward profile for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$7.67

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

The Phase 3 upLIFT study in tHI fails to meet its primary endpoint or shows unexpected safety concerns in H2 2026. The FDA rejects the sunRIZE dataset for cHI, requiring a completely new, costly Phase 3 trial. Cash burn accelerates, forcing highly dilutive equity financing as the cash runway depletes.

Base CaseCentral scenario

$9.1050%

The Phase 3 upLIFT study in tHI meets its primary endpoint in H2 2026, de-risking the commercial launch of ersodetug in the US with projected peak sales of $850 million. The FDA requests additional clinical data or a modified confirmatory study for cHI, delaying the program but keeping the long-term opportunity intact. RZ402 continues steady clinical progress in DME.

Bull CaseUpside scenario

$14.0030%

The Phase 3 upLIFT study in tumor hyperinsulinism (tHI) delivers highly positive topline results in H2 2026, leading to a successful BLA submission. Concurrently, the FDA accepts Rezolute's comprehensive datasets for the sunRIZE study in congenital hyperinsulinism (cHI), establishing a viable regulatory path without requiring a full new Phase 3 trial. RZ402 advances into Phase 2b/3 for diabetic macular edema (DME) with a strong corporate partnership, unlocking substantial non-dilutive funding.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical proof-of-concept in tumor hyperinsulinism (tHI) with 75% of interim patients in the upLIFT study achieving complete discontinuation of IV glucose support.
Ersodetug (RZ358) targets downstream insulin receptor over-activation, making it universally applicable to various forms of hyperinsulinism.
Robust cash position of $167.9 million (as of June 30, 2025) provides runway to advance key clinical programs through major H2 2026 catalysts.
Diversified pipeline with RZ402, a promising oral plasma kallikrein inhibitor for diabetic macular edema (DME), which has completed Phase 2 studies.

Key Investment Risks

Regulatory uncertainty surrounding the congenital hyperinsulinism (cHI) program after the Phase 3 sunRIZE study failed to meet its primary endpoint.
High dependence on a single lead asset (ersodetug) for near-term commercialization and valuation.
Pre-revenue stage with ongoing high research and development expenses, leading to persistent net losses ($16.2 million in Q3 fiscal 2026).
Potential for clinical trial delays, enrollment challenges, or unexpected safety signals in ongoing studies.

Thesis Invalidation Triggers

Failure of the Phase 3 upLIFT study in tumor hyperinsulinism to meet its primary endpoint in H2 2026.
Definitive FDA rejection of the sunRIZE clinical dataset, requiring a full, unfeasible Phase 3 trial for cHI approval.
Inability to secure a clinical or commercial partner for RZ402, leading to increased cash burn or program suspension.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.